CEO ousted as Valion Bio (VBIO) wins reverse split power
Rhea-AI Filing Summary
Valion Bio, Inc. entered into a letter agreement with 3i, LP for a new funding tranche under its existing Series B Preferred Purchase Agreement. The company agreed to issue 1,500 Series B Non-Voting Convertible Preferred Shares at $1,000 per share plus related Series B warrants for an aggregate purchase price of $1,500,000, with closing expected on or about August 17, 2026, in a transaction exempt from registration under Section 4(a)(2) and/or Rule 506(b).
Valion also agreed that 3i and other investors will receive payments under a new Royalty Agreement equal to 5% of gross revenue of subsidiary Velocity Bioworks, Inc. from third parties for 10 years. Lisa Wolf was appointed Chief Operating Officer while continuing as Chief Financial Officer, and Michael K. Handley was terminated as Chief Executive Officer, both effective August 16, 2026.
At an August 14, 2026 special meeting, stockholders approved granting the board authority to implement a reverse stock split at a ratio between 1-for-5 and 1-for-50 within twelve months, and also approved a proposal allowing adjournment of the meeting to solicit additional proxies if needed.
Positive
- New funding of $1,500,000 via Series B preferred stock and warrants provides additional capital.
- Royalty Agreement ties investor returns to 5% of gross revenue from Velocity Bioworks, aligning incentives with subsidiary performance.
Negative
- Royalty Agreement obligates payment of 5% of gross revenue from Velocity Bioworks for 10 years, reducing future gross receipts from that business.
- Stockholders authorized a potential 1-for-5 to 1-for-50 reverse stock split, which can be associated with share consolidation and perceived listing or price pressures.
- Termination of Chief Executive Officer Michael K. Handley on August 16, 2026 introduces leadership transition risk.
Filing Explained
The filing limits the currently agreed funding to a
8-K Event Classification
6 items: 1.01, 3.02, 5.02, 5.07, 8.01, 9.01
6 items
Item 1.01
Entry into a Material Definitive Agreement
Business
The company signed a significant contract such as a merger agreement, credit facility, or major partnership.
Item 3.02
Unregistered Sales of Equity Securities
Securities
The company sold equity securities in a private placement or other unregistered transaction.
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
New Series B Preferred Issuance: 1,500 shares
New Funding Tranche: $1,500,000
Maximum Series B Program Size: 8,400 shares / $8,400,000
+5 more
8 metrics
New Series B Preferred Issuance
1,500 shares
Series B Non-Voting Convertible Preferred Stock to 3i at $1,000 per share
New Funding Tranche
$1,500,000
Aggregate purchase price for August 17, 2026 Series B preferred and warrants closing
Maximum Series B Program Size
8,400 shares / $8,400,000
Series B Preferred Shares and warrants available under April 29, 2025 purchase agreement
Royalty Rate
5% of gross revenue
Royalty on Velocity Bioworks, Inc. gross revenue from third parties for ten years
Royalty Term
10 years
Duration of 5% gross revenue royalty to 3i and other purchasers
Common Shares Outstanding
4,151,259 shares
Common stock issued and outstanding as of July 7, 2026 record date
Shares Represented at Meeting
1,940,835 shares (46.75%)
Common shares represented at August 14, 2026 special meeting
Reverse Split Range
1-for-5 to 1-for-50
Board-authorized reverse stock split ratio range approved by stockholders
Key Terms
Series B Non-Voting Convertible Preferred Stock, Series B Warrants, Royalty Agreement, reverse stock split, +2 more
6 terms
Series B Non-Voting Convertible Preferred Stock financial
"purchase and sale of up to 8,400 shares of the Company’s Series B Non-Voting Convertible Preferred Stock"
A Series B non-voting convertible preferred stock is a class of company shares that gives holders financial priority—such as fixed dividends and first claim on assets if the company is sold—while not granting voting rights. It can be converted into regular common shares under set conditions, which matters to investors because conversion can increase upside participation but also dilute existing owners; the preference reduces downside risk like a safety buffer.
Series B Warrants financial
"and warrants (“Series B Warrants”) to purchase shares of the Company’s common stock"
Series B warrants are contracts issued alongside a company's Series B financing that give the holder the right to buy a set number of shares at a fixed price within a specified time. For investors, they matter because they can provide leveraged upside if the company grows, or they can dilute existing shareholders when exercised—like a coupon promising a future share at a known price that can add value or change ownership stakes.
Royalty Agreement financial
"will enter into a royalty agreement, dated August 17, 2026 (the “Royalty Agreement”)"
A royalty agreement is a contract that lets one party use an asset—like a patent, brand, mineral rights, or creative work—in exchange for regular payments tied to sales, production, or revenue. For investors it matters because royalties create predictable income streams or obligations that affect a company’s cash flow, valuation and risk profile, similar to collecting rent from a tenant or paying a landlord for use of property.
reverse stock split financial
"to effect a reverse stock split of all of its issued and outstanding shares"
A reverse stock split reduces a company's number of outstanding shares while raising the price per share proportionally, so the total value of each investor's holding is unchanged; a 1-for-10 split turns 100 shares worth $1 each into 10 shares worth $10 each. Companies often do this to regain compliance with an exchange's minimum price rule or to attract investors who avoid very low-priced stocks.
unregistered sales of equity securities regulatory
"Item 3.02 Unregistered Sales of Equity Securities."
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
What new financing did Valion Bio (VBIO) secure with 3i, LP in August 2026?
Valion Bio agreed to issue 1,500 Series B Preferred Shares at $1,000 per share plus Series B warrants to 3i, LP for aggregate proceeds of $1,500,000. The closing is expected on or about August 17, 2026 under an existing purchase agreement.
What are the key terms of the Royalty Agreement disclosed by Valion Bio (VBIO)?
3i and other investors will receive cash payments equal to 5% of gross revenue of subsidiary Velocity Bioworks, Inc. from third parties for 10 years. This obligation applies under a Royalty Agreement dated August 17, 2026.
What leadership changes did Valion Bio (VBIO) announce on August 16, 2026?
Valion Bio appointed Lisa Wolf as Chief Operating Officer while she continues as Chief Financial Officer. On the same date, Michael K. Handley was terminated from his position as Chief Executive Officer, reflecting a significant executive leadership change.
What reverse stock split authority did Valion Bio (VBIO) stockholders approve?
Stockholders approved granting the board discretionary authority to implement a reverse stock split between 1-for-5 and 1-for-50 of issued and outstanding common shares within twelve months from the August 14, 2026 special meeting, without further stockholder approval.
What were the preliminary voting results for Valion Bio (VBIO)’s reverse split proposal?
The reverse split authorization (Proposal No. 1) received 1,243,030 votes for, 697,127 against, and 678 abstentions, with 0 broker non-votes. These preliminary results approved granting the board authority to effect the reverse stock split.
Were preferred stockholders of Valion Bio (VBIO) allowed to vote at the August 2026 special meeting?
Holders of Series A, Series B, and Series C Non-Voting Convertible Preferred Stock as of the record date were not entitled to vote on any matters at the special meeting. Only record holders of common stock could vote on the proposals presented.
AI-generated analysis. How Rhea-AI works. Not financial advice.
